How safe and manageable is a new intravenous immunoglobulin therapy in adults living with primary immunodeficiency?

<p dir="ltr">This plain language summary reflects the content of the following scientific abstract: 'Safety and Tolerability of a New Intravenous Immunoglobulin 10% (KIg10) in Primary Immunodeficiency Adult Patients,' presented at the International Primary Immunodeficiencies Congress (IPIC; November 5–7, 2025; Prague, Czech Republic). This was previously presented at the 2025 Clinical Immunology Society (CIS) Annual Meeting: Immune Deficiency & Dysregulation North American Conference (Philadelphia, PA, USA; May 1–4, 2025). For more information on the study, please visit: https://clinconnect.io/trials/NCT01581593</p><p dir="ltr">The purpose of this plain language summary is to help you to understand the findings from recent research. This summary reports the results of a single study. The results of the study may differ from those of other studies. Health professionals should make treatment decisions based on all available evidence, not on the results of a single study.</p><p dir="ltr">Writing and editorial support for this summary was provided by Alison Halliday, PhD, Lauri Arnstein Williams, MA, MBBS, Simon Stones, PhD, ISMPP CMPP™, and Sam Leeves, BA, at Amica Scientific, and funded by Kedrion Biopharma, Inc. The original authors of the scientific abstract were involved in reviewing this summary.</p>